

Kevin M Alexander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9107781/publications.pdf>

Version: 2024-02-01

30
papers

1,172
citations

566801

15
h-index

500791

28
g-index

30
all docs

30
docs citations

30
times ranked

1795
citing authors

#	ARTICLE	IF	CITATIONS
1	AL (Light-Chain) Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1323-1341.	1.2	443
2	Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 962.	3.8	116
3	Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015. <i>JAMA Cardiology</i> , 2018, 3, 865.	3.0	71
4	A V3 Loop-Dependent gp120 Element Disrupted by CD4 Binding Stabilizes the Human Immunodeficiency Virus Envelope Glycoprotein Trimer. <i>Journal of Virology</i> , 2010, 84, 3147-3161.	1.5	64
5	High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning. <i>JAMA Cardiology</i> , 2022, 7, 386.	3.0	63
6	Harnessing Cardiac Regeneration as a Potential Therapeutic Strategy for AL Cardiac Amyloidosis. <i>Current Cardiology Reports</i> , 2020, 22, 1.	1.3	53
7	Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. <i>Circulation</i> , 2020, 141, 751-767.	1.6	48
8	Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. <i>JACC: Heart Failure</i> , 2020, 8, 461-468.	1.9	46
9	Coronavirus disease 2019 in heart transplant recipients: Risk factors, immunosuppression, and outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 926-935.	0.3	36
10	Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities. <i>Nature Reviews Cardiology</i> , 2020, 17, 533-535.	6.1	34
11	Novel pharmacotherapies for cardiac amyloidosis. , 2017, 180, 129-138.		29
12	Prevalence and Outcomes of p.Val142Ile <i>TTR</i> Amyloidosis Cardiomyopathy: A Systematic Review. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003356.	1.6	25
13	Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. <i>Circulation: Heart Failure</i> , 2021, 14, e007957.	1.6	24
14	Phosphorylation of Src by phosphoinositide 3-kinase regulates beta-adrenergic receptor-mediated EGFR transactivation. <i>Cellular Signalling</i> , 2016, 28, 1580-1592.	1.7	21
15	Mortality From Heart Failure and Dementia in the United States: CDC WONDER 1999â€“2016. <i>Journal of Cardiac Failure</i> , 2019, 25, 125-129.	0.7	19
16	Mechanical Circulatory Support for Advanced Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 549-565.	0.4	18
17	Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis. <i>Current Cardiovascular Risk Reports</i> , 2021, 15, 1.	0.8	9
18	Emerging Therapies for Transthyretin Cardiac Amyloidosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 40.	0.4	8

#	ARTICLE	IF	CITATIONS
19	MicroRNA-21 regulates right ventricular remodeling secondary to pulmonary arterial pressure overload. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 154, 106-114.	0.9	8
20	True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis. <i>Haematologica</i> , 2018, 103, e374-e376.	1.7	6
21	Challenges and the innovations in the care of advanced heart failure patients during COVID-19. <i>Heart Failure Reviews</i> , 2022, 27, 235-238.	1.7	6
22	Trends and causes of hospitalizations in patients with amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 177-178.	1.4	5
23	Bone Scintigraphy Imaging for Transthyretin Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1322-1324.	2.3	4
24	Recipe for Success in Transthyretin Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1232-1234.	2.3	4
25	Mistaken Identity. <i>JACC: CardioOncology</i> , 2021, 3, 594-597.	1.7	4
26	Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell Dyscrasias. <i>Cardiology Clinics</i> , 2019, 37, 487-495.	0.9	3
27	Management of Cardiac Amyloidosis: Doâ€™s and Donâ€™ts. <i>Canadian Journal of Cardiology</i> , 2020, 36, 444-446.	0.8	2
28	Transthyretin Cardiac Amyloidosis in the Elderlyâ€”Tip of a Heart Failure Iceberg?. <i>JAMA Cardiology</i> , 2021, 6, 979.	3.0	2
29	Advances in the Diagnosis and Management of Transthyretin Amyloid Cardiomyopathy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	1
30	Decoding the Nanoenvironment in Cardiac Amyloidosis Through Proteomics. <i>JACC: CardioOncology</i> , 2020, 2, 644-646.	1.7	0